@misc{10818/59850,
year = {2023},
url = {http://hdl.handle.net/10818/59850},
abstract = {Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC.},
publisher = {Frontiers in Pharmacology},
title = {An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean},
doi = {10.3389/fphar.2023.1175737},
author = {Salas Hernández A. and Galleguillos M. and Carrasco M. and López Cortés A. and Redal M.A. and Fonseca Mendoza D. and Esperón P. and González Martínez F. and Lares Asseff I. and Lazarowski A. and Loera Castañeda V. and Remírez D. and Martínez M.F. and Vargas R. and Rios Santos F. and Macho A. and Cayún J.P. and Perez G.R. and Gutierrez C. and Cerpa L.C. and Leiva T. and Calfunao S. and Xajil L. and Sandoval C. and Suárez M. and Gonzalez A. and Echeverría Garcés G. and Sullón Dextre L. and Cordero García E. and Morales A.R. and Avendaño A. and Sánchez E. and Bastone L.C. and Lara C. and Zuluaga Arias P. and Soler A.M. and Da Luz J. and Burgueño Rodríguez G. and Vital M. and Reyes Reyes E. and Huaccha A. and Ariza Y.V. and Tzul N. and Rendón A.L. and Serrano R. and Acosta L. and Motta Pardo A. and Beltrán Angarita L. and Brand E. and Jiménez M.A. and Hidalgo Lozada G.M. and Romero Prado M.M.J. and Escobar Castro K. and Umaña Rivas M. and Vivas J.D. and Lagos P. and Martínez Y.B. and Quesada S. and Calfio C. and Arias M.L. and Lavanderos M.A. and Cáceres D.D. and Salazar Granara A. and Varela N.M. and Quiñones L.A.},
}